Thulium Laser and Growth Factors for Androgenetic Alopecia
NCT ID: NCT07079657
Last Updated: 2025-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2023-12-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity.
Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Androgenetic Alopecia in Males and Females
NCT01437163
Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia
NCT04882969
Hair Regeneration in Androgenetic Alopecia
NCT06066827
Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss
NCT05970809
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
NCT05365360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Thulium laser + growth factor serum + LED
Thulium laser + growth factor serum + LED
Thulium laser + growth factor serum + LED
3 sessions at intervals of 6 weeks
Thulium laser + growth factor serum
Thulium laser + growth factor serum
Thulium laser + growth factor serum
3 sessions at intervals of 6 weeks
Thulium laser
Thulium laser
Thulium laser
3 sessions at intervals of 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thulium laser + growth factor serum + LED
3 sessions at intervals of 6 weeks
Thulium laser + growth factor serum
3 sessions at intervals of 6 weeks
Thulium laser
3 sessions at intervals of 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Good general health, no relevant previous illnesses
* Presence of an AGA
* Cognitive ability and willingness to give consent (informed consent)
* Be willing and able to attend follow-up visits
Exclusion Criteria
* Pregnant or breastfeeding women
* Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs
* Significant scarring of the region to be treated
* Significant open wounds or lesions in the region to be treated
* Metallic implants in the head region
* Mental illnesses (psychoses, body perception disorders)
* Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks
* Resurfacing (fractional, ablative, non-ablative) of the affected region \< 2 months before and during the study period
* Tendency to excessive scarring
* Lack of informed consent and/or data protection declarations
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitätsklinikum Hamburg-Eppendorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lynhda Nguyen
Dr. med.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Hamburg-Eppendorf
Hamburg, City state of Hamburg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.